FDA-Approved PD-L1 Companion Diagnostic Expanded to Esophageal and GEJ Carcinoma
The companion diagnostic can now help identify patients with esophageal or gastroesophageal junction carcinoma who may be eligible for pembrolizumab treatment.
Latest Articles
Editor's Top Picks
Ordering Both ESR and CRP Tests Could Save Hospitals Nearly $10 Million Per Year, Study Finds
A peer-reviewed economic analysis challenges the assumption that erythrocyte sedimentation rate and C-reactive protein tests are interchangeable, finding that combined testing reduces misdiagnoses and lowers overall costs.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
AI-Powered Virtual Staining Now Available as On-Premises Hardware for Pathology Labs
Pictor Labs has introduced an on-premises hardware system for AI-powered virtual staining, enabling pathology labs to generate digital stains locally without transferring tissue images to external cloud infrastructure.
Equipment & Supply Spotlight
12 Life Science Startups Named to SLAS Europe 2026 Innovation Showcase Program
Emerging companies from six countries will exhibit enabling technologies at the Society of Laboratory Automation and Screening's annual European conference in Vienna this May.
News, Know-How & Standards
Disease Detection & Understanding
C2N Diagnostics’ eMTBR-tau243 Plasma Assay Used in Alzheimer’s Phase 3 Trial Dataset
The biomarker showed independent associations with cognitive and functional decline, offering complementary information alongside p-tau217 in early symptomatic Alzheimer's disease.
